Get started
Author

Toshiaki Nojima

Observed names: Nojima, Toshiaki, T. Nojima, TOSHIAKI NOJIMA
Institution: Kowa (Japan)
ORCID: 0000-0001-9717-985X
Observed ORCID: 0000-0001-9717-985X
OpenAlex ID: A5071183903
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
2021 · Atsushi Nakajima, Yuichiro Eguchi, et al. · Alimentary Pharmacology & Therapeutics · 225
PDF
Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials
2021 · Koutaro Yokote, Shizuya Yamashita, et al. · Cardiovascular Diabetology · 49
PDF
Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination
2019 · Shizuya Yamashita, Hidenori Arai, et al. · International Journal of Molecular Sciences · 49
PDF
Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin
2019 · Akihiro Yoshida, Yasuhiro Matsubayashi, et al. · The Journal of Clinical Endocrinology & Metabolism · 30
PDF
Ripasudil–Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials
2022 · Hidenobu Tanihara, Tetsuya Yamamoto, et al. · American Journal of Ophthalmology · 22
PDF
Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance
2020 · T. Nojima, Y. Matsubayashi, et al. · Diabetic Medicine · 13
PDF
Predictors of the response of HbA1c and body weight after SGLT2 inhibition
2017 · T. Abe, Y. Matsubayashi, et al. · Diabetes & Metabolism · 12
Influence of SGLT2 Inhibitor on Resting Heart Rate (RHR) and Factors Related to Its Changes
2018 · YASUHIRO MATSUBAYASHI, TOSHIAKI NOJIMA, et al. · Diabetes · 11
Evaluation of Data Errors and Monitoring Activities in a Trial in Japan Using a Risk-Based Approach Including Central Monitoring and Site Risk Assessment
2021 · Hidenobu Kondo, Tomoaki Kamiyoshihara, et al. · Therapeutic Innovation & Regulatory Science · 6
PDF
Pmu91 Current Trend of Utility Values in National Institute for Health and Care Excellence (nice) Technology Appraisal Guidance
2019 · M. Azuma, T. Nojima, et al. · Value in Health · 2
PDF
Generative AI and Clinical Development: Exploring the Frontier of AI Governance Utilizing Generative AI-Conceptual Framework for AI Governance in Clinical Development
2026 · Munenori Takata, Daisuke Ichikawa, et al. · Journal of the Society for Clinical Data Management
Response of lipoproteins to a meal tolerance test in patients with type 2 diabetes and hypertriglyceridemia
2022 · S. Yamashita, H. Arai, et al. · Atherosclerosis
PDF
Untitled
2021 · J. Young, R. Adams, et al. · The Applied Computational Electromagnetics Society Journal (ACES)
1133-P: Association of Higher Baseline BNP Levels with a Greater Reduction in Plasma Volume and Increase in Beta-Hydroxybutyrate via the SGLT2 Inhibitor Tofogliflozin in Type 2 Diabetes
2020 · AKIHIRO YOSHIDA, YASUHIRO MATSUBAYASHI, et al. · Diabetes
1125-P: Association of Plasma Volume with Body Weight and BNP after Long-Term Administration and Subsequent Withdrawal of the SGLT2 Inhibitor Tofogliflozin
2020 · YASUHIRO MATSUBAYASHI, AKIHIRO YOSHIDA, et al. · Diabetes
1215-P: Adipose Tissue Insulin Resistance Predicts Ketosis via an SGLT2 Inhibitor
2019 · YASUHIRO MATSUBAYASHI, AKIHIRO YOSHIDA, et al. · Diabetes
1219-P: Enhanced Response in Serum Ketone Level in Men Compared with Women by Administration of SGLT2 Inhibitor
2019 · AKIHIRO YOSHIDA, YASUHIRO MATSUBAYASHI, et al. · Diabetes
1205-P: Baseline Lactate Level Is a Useful Predictor for Weight Loss after Long-Term SGLT2 Inhibitor Treatment
2019 · TOSHIAKI NOJIMA, YASUHIRO MATSUBAYASHI, et al. · Diabetes
Works count: 20
Citation count: 419
H-index: 8
I10-index: 8
Year
Topic
Type